📊 PRCT Key Takeaways
Is PROCEPT BioRobotics Corp (PRCT) a Good Investment?
PROCEPT demonstrates strong revenue growth of 37.2% YoY with excellent 64.9% gross margins, indicating solid product-market fit and pricing power. However, significant operating losses (-39.2% margin) and negative free cash flow (-$41M) reveal the company is not yet profitable despite healthy gross margins, requiring operational leverage improvement. The fortress balance sheet with $245.6M cash and low debt (0.15x) provides 6+ year runway, but a credible path to profitability must emerge.
Why Buy PROCEPT BioRobotics Corp Stock? PRCT Key Strengths
- Revenue growth of 37.2% YoY demonstrates strong market demand for surgical robotics
- Gross margin of 64.9% indicates strong pricing power and efficient core operations
- Fortress balance sheet: $245.6M cash, 0.15x debt-to-equity, 6.73x current ratio provides substantial runway
PRCT Stock Risks: PROCEPT BioRobotics Corp Investment Risks
- Operating margin of -39.2% and net margin of -38.1% show inability to achieve profitability despite strong gross margins
- Negative operating cash flow of -$38.1M and free cash flow of -$41.0M indicates ongoing cash burn with unclear path to positive FCF
- Operating expenses are not declining relative to revenue growth; company must demonstrate operating leverage to justify continued losses
Key Metrics to Watch
- Operating cash flow trend and timeline to positive FCF
- Operating margin progression toward breakeven as sales scale
- Revenue growth sustainability and gross margin stability
PROCEPT BioRobotics Corp (PRCT) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 6.73x current ratio provides a solid financial cushion.
PRCT Profit Margin, ROE & Profitability Analysis
PRCT vs Healthcare Sector: How PROCEPT BioRobotics Corp Compares
How PROCEPT BioRobotics Corp compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is PROCEPT BioRobotics Corp Stock Overvalued? PRCT Valuation Analysis 2026
Based on fundamental analysis, PROCEPT BioRobotics Corp has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
PROCEPT BioRobotics Corp Balance Sheet: PRCT Debt, Cash & Liquidity
PRCT Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: PROCEPT BioRobotics Corp's revenue has grown significantly by 794% over the 5-year period, indicating strong business expansion. The most recent EPS of $-2.24 indicates the company is currently unprofitable.
PRCT Revenue Growth, EPS Growth & YoY Performance
PRCT Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $69.2M | -$24.7M | $-0.45 |
| Q3 2025 | $58.4M | -$19.6M | $-0.38 |
| Q2 2025 | $53.4M | -$19.6M | $-0.35 |
| Q1 2025 | $44.5M | -$24.7M | $-0.45 |
| Q3 2024 | $35.1M | -$21.0M | $-0.40 |
| Q2 2024 | $33.1M | -$25.3M | $-0.50 |
| Q1 2024 | $24.4M | -$26.0M | $-0.51 |
| Q3 2023 | $20.3M | -$17.2M | $-0.51 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
PROCEPT BioRobotics Corp Dividends, Buybacks & Capital Allocation
PRCT SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for PROCEPT BioRobotics Corp (CIK: 0001588978)
📋 Recent SEC Filings
❓ Frequently Asked Questions about PRCT
What is the AI rating for PRCT?
PROCEPT BioRobotics Corp (PRCT) has an AI rating of HOLD with 63% confidence, based on fundamental analysis of SEC EDGAR filings.
What are PRCT's key strengths?
Claude: Revenue growth of 37.2% YoY demonstrates strong market demand for surgical robotics. Gross margin of 64.9% indicates strong pricing power and efficient core operations.
What are the risks of investing in PRCT?
Claude: Operating margin of -39.2% and net margin of -38.1% show inability to achieve profitability despite strong gross margins. Negative operating cash flow of -$38.1M and free cash flow of -$41.0M indicates ongoing cash burn with unclear path to positive FCF.
What is PRCT's revenue and growth?
PROCEPT BioRobotics Corp reported revenue of $83.1M.
Does PRCT pay dividends?
PROCEPT BioRobotics Corp does not currently pay dividends.
Where can I find PRCT SEC filings?
Official SEC filings for PROCEPT BioRobotics Corp (CIK: 0001588978) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is PRCT's EPS?
PROCEPT BioRobotics Corp has a diluted EPS of $-0.56.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is PRCT a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, PROCEPT BioRobotics Corp has a HOLD rating with 63% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is PRCT stock overvalued or undervalued?
Valuation metrics for PRCT: ROE of -9.1% (sector avg: 15%), net margin of -38.1% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy PRCT stock in 2026?
Our dual AI analysis gives PROCEPT BioRobotics Corp a combined HOLD rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is PRCT's free cash flow?
PROCEPT BioRobotics Corp's operating cash flow is $-38.1M, with capital expenditures of $2.9M. FCF margin is -49.4%.
How does PRCT compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -38.1% (avg: 12%), ROE -9.1% (avg: 15%), current ratio 6.73 (avg: 2).